Skip to main content
SpringerLink
Log in
Book cover

Drug Dosing in Obesity pp 1–12Cite as

Introduction

  • Chapter
  • First Online:

  • 806 Accesses

Abstract

Significant physiological changes in obese patients limit the generalisability of dosing information of antimicrobials to this increasingly prevalent group of patients. Individualised approaches to drug dosing in obese patients are warranted to address the significant changes in the pharmacokinetics of antimicrobials in this patient group. Nevertheless, differences in the chemical, physiological and clinical characteristics of antimicrobials limit the application of established pharmacokinetics in obese patients. Important considerations when designing an antimicrobial regimen include an understanding of the focus of infection, relative susceptibilities of the micro-organism involved, the best match of the body size descriptor for the antimicrobial in question and the renal function of the patients under treatment.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363(9403):157–63.

    Article  Google Scholar 

  2. World Health Organisation. Obesity and overweight. Fact sheet no. 311 (updated January 2015, 30 January 2015). Available from: http://www.who.int/.

  3. Vogtle LK. Measuring body composition: the limitations of body mass index. Dev Med Child Neurol. 2015;57(11):991–2.

    Article  PubMed  Google Scholar 

  4. Organisation WH. Prevelance world map and statistics of Obesity, age 18+ 2014 data 2015 (cited 2015 27/10/2015). Available from: http://gamapserver.who.int/gho/interactive_charts/ncd/risk_factors/obesity/atlas.html.

  5. Falagas ME, Karageorgopoulos DE. Adjustment of dosing of antimicrobial agents for bodyweight in adults. Lancet. 2010;375(9710):248–51.

    Article  PubMed  Google Scholar 

  6. Pai MP. Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults. Pharmacotherapy. 2012;32(9):856–68.

    Article  PubMed  Google Scholar 

  7. Huttunen R, Syrjanen J. Obesity and the risk and outcome of infection. Int J Obes. 2013;37(3):333–40.

    Article  CAS  Google Scholar 

  8. Muscedere JG, Shorr AF, Jiang X, Day A, Heyland DK, Canadian Critical Care Trials G. The adequacy of timely empiric antibiotic therapy for ventilator-associated pneumonia: an important determinant of outcome. J Crit Care. 2012;27(3):322 e7–14.

    Google Scholar 

  9. Pai MP, Bearden DT. Antimicrobial dosing considerations in obese adult patients. Pharmacotherapy. 2007;27(8):1081–91.

    Article  CAS  PubMed  Google Scholar 

  10. Allard S, Kinzig M, Boivin G, Sorgel F, LeBel M. Intravenous ciprofloxacin disposition in obesity. Clin Pharmacol Ther. 1993;54(4):368–73.

    Article  CAS  PubMed  Google Scholar 

  11. Bauer LA, Black DJ, Lill JS. Vancomycin dosing in morbidly obese patients. Eur J Clin Pharmacol. 1998;54(8):621–5.

    Article  CAS  PubMed  Google Scholar 

  12. Muzevich KM, Lee KB. Subtherapeutic linezolid concentrations in a patient with morbid obesity and methicillin-resistant Staphylococcus aureus pneumonia: case report and review of the literature. Ann Pharmacother. 2013;47(6):e25.

    Article  PubMed  Google Scholar 

  13. Corcoran GB, Salazar DE, Schentag JJ. Excessive aminoglycoside nephrotoxicity in obese patients. Am J Med. 1988;85(2):279.

    Article  CAS  PubMed  Google Scholar 

  14. Gauthier TP, Wolowich WR, Reddy A, Cano E, Abbo L, Smith LB. Incidence and predictors of nephrotoxicity associated with intravenous colistin in overweight and obese patients. Antimicrob Agents Chemother. 2012;56(5):2392–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Davies SW, Efird JT, Guidry CA, Dietch ZC, Willis RN, Shah PM, et al. Vancomycin-Associated Nephrotoxicity: The Obesity Factor. Surg Infect (Larchmt). 2015.

    Google Scholar 

  16. Ortiz VE, Kwo J. Obesity: physiologic changes and implications for preoperative management. BMC Anesthesiol. 2015;15:97.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Waki M, Kral JG, Mazariegos M, Wang J, Pierson RN, Jr., Heymsfield SB. Relative expansion of extracellular fluid in obese vs. nonobese women. Am J Physiol. 1991;261(2 Pt 1):E199–203.

    Google Scholar 

  18. Chung EK, Cheatham SC, Fleming MR, Healy DP, Shea KM, Kays MB. Population pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese and nonobese patients. J Clin Pharmacol. 2015;55(8):899–908.

    Article  CAS  PubMed  Google Scholar 

  19. Pai MP, Cojutti P, Pea F. Pharmacokinetics and pharmacodynamics of continuous infusion meropenem in overweight, obese, and morbidly obese patients with stable and unstable kidney function: a step toward dose optimization for the treatment of severe gram-negative bacterial infections. Clin Pharmacokinet. 2015;54(9):933–41.

    Article  CAS  PubMed  Google Scholar 

  20. Sketris I, Lesar T, Zaske DE, Cipolle RJ. Effect of obesity on gentamicin pharmacokinetics. J Clin Pharmacol. 1981;21(7):288–93.

    Article  CAS  PubMed  Google Scholar 

  21. Sturm AW, Allen N, Rafferty KD, Fish DN, Toschlog E, Newell M, et al. Pharmacokinetic analysis of piperacillin administered with tazobactam in critically ill, morbidly obese surgical patients. Pharmacotherapy. 2014;34(1):28–35.

    Article  CAS  PubMed  Google Scholar 

  22. Pai MP, Cojutti P, Pea F. Levofloxacin dosing regimen in severely morbidly obese patients (BMI >/= 40 kg/m(2)) should be guided by creatinine clearance estimates based on ideal body weight and optimized by therapeutic drug monitoring. Clin Pharmacokinet. 2014;53(8):753–62.

    Article  CAS  PubMed  Google Scholar 

  23. Levy BI, Schiffrin EL, Mourad JJ, Agostini D, Vicaut E, Safar ME, et al. Impaired tissue perfusion: a pathology common to hypertension, obesity, and diabetes mellitus. Circulation. 2008;118(9):968–76.

    Article  PubMed  Google Scholar 

  24. Brook RD, Bard RL, Bodary PF, Eitzman DT, Rajagopalan S, Sun Y, et al. Blood pressure and vascular effects of leptin in humans. Metab Syndr Relat Disord. 2007;5(3):270–4.

    Article  CAS  PubMed  Google Scholar 

  25. Hollenstein UM, Brunner M, Schmid R, Muller M. Soft tissue concentrations of ciprofloxacin in obese and lean subjects following weight-adjusted dosing. Int J Obes Relat Metab Disord. 2001;25(3):354–8.

    Article  CAS  PubMed  Google Scholar 

  26. Huttunen R, Syrjanen J. Obesity and the risk and outcome of infection. Int J Obes (Lond). 2013;37(3):333–40.

    Article  CAS  Google Scholar 

  27. Wei JL, Leung JC, Loong TC, Wong GL, Yeung DK, Chan RS, et al. Prevalence and severity of nonalcoholic fatty liver disease in non-obese patients: a population study using proton-magnetic resonance spectroscopy. Am J Gastroenterol. 2015;110(9):1306–14.

    Article  CAS  PubMed  Google Scholar 

  28. Brill MJ, Diepstraten J, van Rongen A, van Kralingen S, van den Anker JN, Knibbe CA. Impact of obesity on drug metabolism and elimination in adults and children. Clin Pharmacokinet. 2012;51(5):277–304.

    Article  CAS  PubMed  Google Scholar 

  29. Merrell MD, Cherrington NJ. Drug metabolism alterations in nonalcoholic fatty liver disease. Drug Metab Rev. 2011;43(3):317–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Pai MP, Lodise TP. Steady-state plasma pharmacokinetics of oral voriconazole in obese adults. Antimicrob Agents Chemother. 2011;55(6):2601–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Hall JE, Guyton AC. Guyton and Hall textbook of medical physiology. 2011.

    Google Scholar 

  32. Pai MP. Estimating the glomerular filtration rate in obese adult patients for drug dosing. Adv Chronic Kidney Dis. 2010;17(5):e53–62.

    Article  PubMed  Google Scholar 

  33. Alicic RZ, Patakoti R, Tuttle KR. Direct and indirect effects of obesity on the kidney. Adv Chronic Kidney Dis. 2013;20(2):121–7.

    Article  PubMed  Google Scholar 

  34. Amann K, Benz K. Structural renal changes in obesity and diabetes. Semin Nephrol. 2013;33(1):23–33.

    Article  PubMed  Google Scholar 

  35. Dvorchik BH, Damphousse D. The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects. J Clin Pharmacol. 2005;45(1):48–56.

    Article  CAS  PubMed  Google Scholar 

  36. Velissaris D, Karamouzos V, Marangos M, Pierrakos C, Karanikolas M. Pharmacokinetic changes and dosing modification of aminoglycosides in critically ill obese patients: a literature review. J Clin Med Res. 2014;6(4):227–33.

    CAS  PubMed  PubMed Central  Google Scholar 

  37. Giuliano C, Haase KK, Hall R. Use of vancomycin pharmacokinetic–pharmacodynamic properties in the treatment of MRSA infections. Expert Rev Anti-infective Ther. 2010;8(1):95–106.

    Article  Google Scholar 

  38. Panidis D, Markantonis SL, Boutzouka E, Karatzas S, Baltopoulos G. Penetration of gentamicin into the alveolar lining fluid of critically ill patients with ventilator-associated pneumonia. Chest. 2005;128(2):545–52.

    Article  CAS  PubMed  Google Scholar 

  39. Chen SY, Liao CH, Wang JL, Chiang WC, Lai MS, Chie WC, et al. Method-specific performance of vancomycin MIC susceptibility tests in predicting mortality of patients with methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother. 2014;69(1):211–8.

    Article  CAS  PubMed  Google Scholar 

  40. Zaidi STR, Al Omram S, Al Aithan ASM, Al Sultan M. Efficacy and safety of low-dose colistin in the treatment for infections caused by multidrug-resistant gram-negative bacteria. J Clin Pharm Ther. 2014;39(3):272–6.

    Google Scholar 

  41. Gillespie EL, Kuti JL, Nicolau DP. Pharmacodynamics of antimicrobials: treatment optimisation. Expert Opin Drug Metab Toxicol. 2005;1(3):351–61.

    Article  CAS  PubMed  Google Scholar 

  42. Zelenitsky SA, Ariano RE. Support for higher ciprofloxacin AUC 24/MIC targets in treating Enterobacteriaceae bloodstream infection. J Antimicrob Chemother. 2010;65(8):1725–32.

    Article  CAS  PubMed  Google Scholar 

  43. Wurtz R, Itokazu G, Rodvold K. Antimicrobial dosing in obese patients. Clin Infect Dis. 1997;25(1):112–8.

    Article  CAS  PubMed  Google Scholar 

  44. Payne KD, Hall RG 2nd. Dosing of antibacterial agents in obese adults: does one size fit all? Expert Rev Anti Infect Ther. 2014;12(7):829–54.

    Article  CAS  PubMed  Google Scholar 

  45. Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. Quantification of lean bodyweight. Clin Pharmacokinet. 2005;44(10):1051–65.

    Article  PubMed  Google Scholar 

  46. Denetclaw TH, Yu MK, Moua M, Dowling TC, Steinke D. Performance of a divided-load intravenous vancomycin dosing strategy for obese patients. Ann Pharmacother. 2015;49(8):861–8.

    Article  PubMed  Google Scholar 

  47. Reynolds DC, Waite LH, Alexander DP, DeRyke CA. Performance of a vancomycin dosage regimen developed for obese patients. Am J Health Syst Pharm. 2012;69(11):944–50.

    Article  CAS  PubMed  Google Scholar 

  48. Cohen LG, DiBiasio A, Lisco SJ, Hurford WE. Fluconazole serum concentrations and pharmacokinetics in an obese patient. Pharmacotherapy. 1997;17(5):1023–6.

    CAS  PubMed  Google Scholar 

  49. Levey AS, Greene T, Schluchter MD, Cleary PA, Teschan PE, Lorenz RA, et al. Glomerular filtration rate measurements in clinical trials. Modification of Diet in Renal Disease Study Group and the Diabetes Control and Complications Trial Research Group. J Am Soc Nephrol. 1993;4(5):1159–71.

    CAS  PubMed  PubMed Central  Google Scholar 

  50. Demirovic JA, Pai AB, Pai MP. Estimation of creatinine clearance in morbidly obese patients. Am J Health Syst Pharm. 2009;66(7):642–8.

    Article  CAS  PubMed  Google Scholar 

  51. Salazar DE, Corcoran GB. Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass. Am J Med. 1988;84(6):1053–60.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pharmacy, School of Medicine, University of Tasmania, Private Bag 26, Hobart, TAS, 7001, Australia

    Syed Tabish R. Zaidi

Authors
  1. Syed Tabish R. Zaidi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Syed Tabish R. Zaidi .

Editor information

Editors and Affiliations

  1. Division of Pharmacy, School of Medicine, University of Tasmania School of Medicine, Hobart, Tasmania, Australia

    Syed Tabish R. Zaidi

  2. School of Medicine and School of Pharmacy, Burns, Trauma and Critical Care Res Cntr, University of Queensland Burns, Trauma and Critical Care Res Cntr, Brisbane, Queensland, Australia

    Jason A. Roberts

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Zaidi, S.T.R. (2016). Introduction. In: Zaidi, S., Roberts, J. (eds) Drug Dosing in Obesity. Springer, Cham. https://doi.org/10.1007/978-3-319-44034-7_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-44034-7_1

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-44032-3

  • Online ISBN: 978-3-319-44034-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation